TrialFrontiers in immunology2022

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.

Hujun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.